Dexamethasone conjugation to an Avidin-Nucleic-Acid-NanoASsembly eliminates the steroid plasma absorption, enhancing selective lung tropism in a murine model of pulmonary fibrosis
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Despite their anti-inflammatory activity, corticosteroids are limited in clinic due to poor selectivity and their side effects. The ability to cross biological barriers makes them powerful yet unspecific, leading to toxicity and a low therapeutic index that limits their chronic use in autoimmune, inflammatory, and infectious diseases. It is needed another approachfor innovative targeted delivery strategies. This study aimed at investigating if the dexamethasone conjugation to Avidin-Nucleic-Acid-NanoASsembly (ANANAS) could allow its selective lung release in the bleomycin-induced pulmonary fibrosis model. Since recent evidence showed a selective ANANAS accumulation in macrophage lysosomes in a liver fibrosis model, an acid-sensitive hydrazone linker was used to facilitate dexamethasone release into pulmonary macrophages, key players in lung fibrosis. Systemic ANANAS-Dex administration in healthy mice showed no dexamethasone release in plasma or peripheral organs, with delivery exclusively targeting the liver, independent of the health status. While this confirmed the nanocarrier safety, it underscored the influence of the administration route, rather than the disease state, on ANANAS-Dex tropism. The study on intranasal administration highlighted that: 1) free Dex circulates in the bloodstream, while ANANAS keeps the drug confined in the lungs; 2) ANANAS-Dex results in sustained drug release in the lungs, enhancing the lungs/plasma-peripheral organs ratio; 3) fibrotic mice exhibited prolonged kinetics and macrophage targeting. Based on the biodistribution and pharmacokinetics studies, it is possible to achieve controlled and safe steroid release in lung disorders, reducing systemic toxicity and potentially enhancing clinical compliance.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Dexamethasone conjugation to an Avidin-Nucleic-Acid-NanoASsembly eliminates the steroid plasma absorption, enhancing selective lung tropism in a murine model of pulmonary fibrosis
- Date Crossref
- 17/08/2025
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Mario Negri Institute for Pharmacological Research pays non établi dans la noticeOrganisation à but non lucratif
-
University of Milano-Bicocca Department of Biotechnology and Biosciences pays non établi dans la noticeUniversité ou école supérieure
-
University of Padua pays non établi dans la noticeUniversité ou école supérieure
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedale - Università Padova pays non établi dans la noticeÉtablissement de santé
-
Department of Biochemistry and Molecular Pharmacology pays non établi dans la noticeInstitution
-
University of Padova Pharmaceutical and Pharmacological Sciences Department (DSF) pays non établi dans la noticeUniversité ou école supérieure
-
Department of Environmental Health Sciences pays non établi dans la noticeInstitution
-
Department of Respiratory Physiopathology pays non établi dans la noticeInstitution
Mario Negri Institute for Pharmacological Research, Department of Biotechnology and Biosciences — University of Milano-Bicocca et University of Padua, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.